1月26日，微电生理跌5.10%，成交额2.43亿元。两融数据显示，当日微电生理获融资买入额4009.15万 元，融资偿还2481.21万元，融资净买入1527.95万元。截至1月26日，微电生理融资融券余额合计3.66亿 元。 资料显示，上海微创电生理医疗科技股份有限公司位于上海市浦东新区周浦镇天雄路588弄1-28号第28 幢，成立日期2010年8月31日，上市日期2022年8月31日，公司主营业务涉及电生理介入诊疗与消融治疗 领域创新医疗器械研发、生产和销售。主营业务收入构成为：导管类产品71.77%，其他产品20.22%， 设备类产品7.24%，租赁服务0.77%。 截至9月30日，微电生理股东户数9580.00，较上期增加9.00%；人均流通股13033股，较上期减少 8.26%。2025年1月-9月，微电生理实现营业收入3.36亿元，同比增长15.65%；归母净利润4192.06万元， 同比增长0.46%。 机构持仓方面，截止2025年9月30日，微电生理十大流通股东中，汇添富创新医药混合A（006113）位 居第一大流通股东，持股472.84万股，相比上期增加30.86万股。汇添富医疗服务灵活配 ...

1月26日，微电生理跌5.03%，截至发稿，报24.57元/股，成交2.03亿元，换手率6.51%，总市值115.63亿 元。 资料显示，上海微创电生理医疗科技股份有限公司位于上海市浦东新区周浦镇天雄路588弄1-28号第28 幢，成立日期2010年8月31日，上市日期2022年8月31日，公司主营业务涉及电生理介入诊疗与消融治疗 领域创新医疗器械研发、生产和销售。主营业务收入构成为：导管类产品71.77%，其他产品20.22%， 设备类产品7.24%，租赁服务0.77%。 从基金十大重仓股角度 数据显示，鹏华基金旗下1只基金重仓微电生理。鹏华创新医药混合A（021308）四季度持有股数14.87 万股，占基金净值比例为7.17%，位居第十大重仓股。根据测算，今日浮亏损失约19.33万元。 李建国累计任职时间220天，现任基金资产总规模4799.96万元，任职期间最佳基金回报5.09%， 任职期 间最差基金回报4.72%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

Core Viewpoint - Microelectrophysiology has shown a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth in the medical device sector [1][2]. Group 1: Stock Performance - As of January 8, Microelectrophysiology's stock price increased by 2.08%, reaching 25.58 CNY per share, with a trading volume of 89.22 million CNY and a turnover rate of 2.83% [1]. - Year-to-date, the stock price has risen by 10.50%, with notable increases of 8.85% over the last five trading days, 15.02% over the last 20 days, and 22.28% over the last 60 days [2]. Group 2: Company Overview - Shanghai Microelectrophysiology Medical Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022. The company specializes in innovative medical devices for electrophysiological intervention and ablation therapy [2]. - The revenue composition of the company includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Microelectrophysiology reported a revenue of 336 million CNY, reflecting a year-on-year growth of 15.65%. The net profit attributable to shareholders was 41.92 million CNY, with a slight increase of 0.46% year-on-year [2]. Group 4: Shareholder Structure - As of September 30, 2025, the largest shareholder is Huatai-PineBridge Innovation Medical Mixed Fund A, holding 4.7284 million shares, an increase of 308,600 shares from the previous period [3]. - Other notable shareholders include Huatai-PineBridge Medical Service Flexible Allocation Mixed Fund A and Hua Bao Zhong Zheng Medical ETF, with changes in their holdings compared to the previous period [3].

Core Viewpoint - Microelectrophysiology experienced a decline of 1.49% on December 31, with a trading volume of 71.91 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On December 31, the financing buy amount for Microelectrophysiology was 14.78 million yuan, while the financing repayment was 21.49 million yuan, resulting in a net financing outflow of 6.71 million yuan [1]. - As of December 31, the total financing and securities lending balance for Microelectrophysiology was 312 million yuan, with the financing balance accounting for 10.75% of the circulating market value, indicating a high level compared to the past year [1]. - The company had no shares repaid in securities lending on December 31, with 7,700 shares sold short, amounting to 178,300 yuan at the closing price, and a securities lending balance of 1.05 million yuan, also at a high level compared to the past year [1]. Business Performance - For the period from January to September 2025, Microelectrophysiology achieved an operating income of 336 million yuan, representing a year-on-year growth of 15.65%, while the net profit attributable to shareholders was 41.92 million yuan, showing a slight increase of 0.46% year-on-year [2]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Microelectrophysiology was 9,580, an increase of 9% from the previous period, while the average circulating shares per person decreased by 8.26% to 13,033 shares [2]. - The top circulating shareholders included Huatai-PineBridge Innovation Medical Mixed A as the largest shareholder with 4.73 million shares, an increase of 308,600 shares, while other significant shareholders saw varying changes in their holdings [3].

Company Overview - Microelectrophysiology, a company based in Shanghai, specializes in innovative medical devices for electrophysiological intervention and ablation therapy, with a total market capitalization of 11.285 billion yuan as of November 20 [1] - The company was established on August 31, 2010, and went public on August 31, 2022 [1] - Revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1] Stock Performance - On November 20, the stock price increased by 5.45%, reaching 23.98 yuan per share, with a trading volume of 63.1665 million yuan and a turnover rate of 2.19% [1] Shareholder Information - Huabao Fund's Huabao Zhongzheng Medical ETF (512170) is among the top ten circulating shareholders, having reduced its holdings by 574,900 shares in the third quarter, now holding 4.0374 million shares, which is 3.23% of the circulating shares [2] - The ETF has a current scale of 26.404 billion yuan and has achieved a year-to-date return of 8.3% [2] Fund Management - The fund manager of Huabao Zhongzheng Medical ETF is Hu Jie, who has a tenure of 13 years and 39 days, managing assets totaling 100.204 billion yuan [3] - The best fund return during Hu Jie's tenure is 183.07%, while the worst return is -98.01% [3]

Core Viewpoint - The stock of Shanghai Microelectronic Physiological Technology Co., Ltd. has experienced fluctuations, with a current price of 23.31 CNY per share, reflecting a year-to-date increase of 22.43% but a recent decline of 4.47% over the last five trading days [1] Group 1: Company Overview - Shanghai Microelectronic Physiological Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022. The company specializes in the research, development, production, and sales of innovative medical devices in the field of electrophysiological intervention and ablation therapy [1] - The company's revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 336 million CNY, representing a year-on-year growth of 15.65%. The net profit attributable to shareholders was 41.92 million CNY, with a slight increase of 0.46% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 9,580, up by 9%. The average number of circulating shares per person decreased by 8.26% to 13,033 shares [2] - The top circulating shareholder is Huatai-PineBridge Innovation Medicine Mixed A, holding 4.7284 million shares, an increase of 308,600 shares from the previous period. Other notable shareholders include Huatai-PineBridge Medical Service Flexible Allocation Mixed A and Hua Bao Zhong Zheng Medical ETF, with varying changes in their holdings [3]

Core Viewpoint - The stock of Microelectrophysiology has experienced fluctuations, with a recent decline of 2.05% and a year-to-date increase of 25.53% [1][2]. Company Overview - Shanghai Microelectrophysiology Medical Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022. The company specializes in innovative medical devices for electrophysiological intervention and ablation treatment [2]. - The revenue composition of the company includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 336 million yuan, representing a year-on-year growth of 15.65%. The net profit attributable to the parent company was 41.92 million yuan, with a slight increase of 0.46% year-on-year [2]. Stockholder Information - As of September 30, 2025, the number of shareholders increased to 9,580, while the average circulating shares per person decreased by 8.26% to 13,033 shares [2]. - The top circulating shareholders include: - Huatai-PineBridge Innovation Medicine Mixed A (006113) as the largest shareholder with 4.7284 million shares, an increase of 308,600 shares from the previous period [3]. - Huatai-PineBridge Medical Service Flexible Allocation Mixed A (001417) as the second-largest shareholder with 4.2609 million shares, a decrease of 298,360 shares [3]. - Hong Kong Central Clearing Limited entered as a new shareholder with 1.8701 million shares [3].

Core Viewpoint - The company, Shanghai MicroPort EP MedTech Co., Ltd., has shown a positive performance in terms of stock price and financial results, indicating growth potential in the medical device sector, particularly in electrophysiology intervention and ablation treatment [1][2]. Financial Performance - As of September 30, 2025, the company achieved a revenue of 336 million yuan, representing a year-on-year growth of 15.65% [2]. - The net profit attributable to shareholders for the same period was 41.92 million yuan, with a slight increase of 0.46% year-on-year [2]. Stock Performance - The stock price of MicroPort EP fell by 2.07% to 24.63 yuan per share on November 10, with a total market capitalization of 11.591 billion yuan [1]. - Year-to-date, the stock has increased by 29.36%, with a 1.78% rise over the last five trading days, 15.63% over the last 20 days, and 9.13% over the last 60 days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 9,580, while the average circulating shares per person decreased by 8.26% to 13,033 shares [2]. - The largest shareholder is Huatai-PineBridge Innovation Medical Mixed A, holding 4.7284 million shares, an increase of 308,600 shares from the previous period [3]. Business Overview - The company specializes in the research, development, production, and sales of innovative medical devices in the field of electrophysiology intervention and ablation treatment [1]. - The revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1].

Core Viewpoint - Microelectrophysiology's stock price has shown a significant increase this year, with a 31.67% rise, indicating strong market interest and potential growth in the medical device sector [1][2]. Financial Performance - For the period from January to September 2025, Microelectrophysiology reported a revenue of 336 million yuan, reflecting a year-on-year growth of 15.65% [2]. - The net profit attributable to shareholders for the same period was 41.92 million yuan, showing a slight increase of 0.46% year-on-year [2]. Stock Market Activity - As of November 7, the stock price of Microelectrophysiology was 25.07 yuan per share, with a trading volume of 1.03 billion yuan and a turnover rate of 3.23%, leading to a total market capitalization of 11.798 billion yuan [1]. - The stock has experienced a 5.03% increase over the last five trading days and a 16.39% increase over the last 20 days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 9,580, while the average number of tradable shares per person decreased by 8.26% to 13,033 shares [2][3]. - The largest shareholder is Huatai-PineBridge Innovation Medicine Mixed A, holding 4.7284 million shares, an increase of 308,600 shares from the previous period [3].

Core Viewpoint - Microelectrophysiology has seen a significant stock price increase, with a 5.16% rise on November 5, reaching 25.90 CNY per share, and a total market capitalization of 12.189 billion CNY [1] Group 1: Company Overview - Shanghai Microelectrophysiology Medical Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022 [1] - The company specializes in the research, development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation therapy [1] - Revenue composition includes catheter products at 71.77%, other products at 20.22%, equipment at 7.24%, and leasing services at 0.77% [1] Group 2: Fund Holdings - One fund under China Europe Fund has a significant holding in Microelectrophysiology, specifically the China Europe CSI 1000 Index Enhanced A (017919), which held 97,300 shares, accounting for 0.42% of the fund's net value [2] - The fund has realized a floating profit of approximately 123,600 CNY today and 291,000 CNY during the five-day price increase [2] - The fund was established on March 2, 2023, with a current size of 239 million CNY and has achieved a year-to-date return of 29.63% [2] Group 3: Fund Manager Performance - The fund manager Qian Yating has a tenure of 4 years and 4 days, with a total asset size of 5.022 billion CNY and a best return of 60.5% during her tenure [3] - Co-manager Song Ting has been in position for 258 days, managing assets of 2.731 billion CNY, with a best return of 30.43% [3]